New scan could sharpen prostate cancer detection
NCT ID NCT04777071
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a special PET scan using a tracer called 68Ga-PSMA-11 can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer at different stages will get the scan. The goal is to see if the scan changes how doctors plan treatment, such as switching from one therapy to another.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium Ga 68 Gozetotide (a radioactive tracer used in PET scans)
What this could lead to
If successful, this imaging method could help doctors more accurately stage prostate cancer and choose the best treatment, potentially improving outcomes.
What could go wrong
This is a phase 2 trial with 141 participants, so results are still preliminary. The scan may not always change management or improve survival, and false positives are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States